Name | Role | Date | Shares | Price | Value |
---|---|---|---|---|---|
Mark J. Gergen | Executive Chairman | 2024-03-01 | 34,157 | $4.13 | $141.07kSell |
Harry J. Leonhardt | GC Chief Compliance Officer | 2024-03-01 | 16,306 | $4.13 | $67.34kSell |
Johanna Mylet | Chief Financial Officer | 2024-03-01 | 18,091 | $4.13 | $74.72kSell |
Brent Warner | President Gene Therapy | 2024-03-01 | 35,739 | $4.13 | $147.60kSell |
Mark J. Gergen | Executive Chairman | 2024-02-01 | 47,162 | $3.41 | $160.82kSell |
Name | Hold | Shares | Value | Type |
---|---|---|---|---|
Fmr LLC | 14.97% | 14,543,647 | $37.96M | Institution |
Malin Life Sciences Holdings Ltd | 12.19% | 11,835,673 | $30.89M | Insider |
Sean Murphy | 9.47% | 9,198,125 | $24.01M | Insider |
Pentwater Capital Management LP | 6.15% | 5,975,000 | $15.59M | Institution |
Pharma Ag Novartis | 6.08% | 5,908,089 | $15.42M | Insider |
Luke Corning | 5.18% | 5,026,177 | $13.12M | Insider |
Blackrock Inc | 5.05% | 4,905,160 | $12.80M | Institution |
Boxer Capital LLC | 4.61% | 4,475,000 | $11.68M | Institution |
Silverarc Capital Management LLC | 3.71% | 3,607,999 | $9.42M | Institution |
Vanguard Group Inc | 3.51% | 3,405,805 | $8.89M | Institution |